



Coronavirus, Its Neurologic Manifestations, and Complications

Mahmoud Reza Ashrafi¹, Reza Azizimalamiri², Reza Shervin Badv¹, Ali Reza Tavasoli¹, Ali Nikkhah¹, Hadi Montazerlotfelahi³, Mohammad Vafae-Shahi⁴ and Morteza Heidari^{1,*}

¹Department of Paediatrics, Division of Paediatric Neurology, Growth and Development Research Center, Children's Medical Centre, Paediatrics Centre of Excellence, Tehran University of Medical Sciences, Tehran, Iran

²Department of Paediatric Neurology, Golestan Medical, Educational, and Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³Department of Paediatric Neurology, Imam Ali Hospital, Alborz University of Medical Sciences, Karaj, Iran

⁴Paediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

*Corresponding author: Department of Paediatric Neurology, Centre of Excellence, Children's Medical Centre, Tehran University of Medical Sciences, Gharib St, P.O. Box: 1419733151, Tehran, Iran. Tel/Fax: +98-2166129252, Email: m-heidari@sina.tums.ac.ir

Received 2020 March 10; Accepted 2020 April 02.

Abstract

Context: We are going to face an epidemic of severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus in our country. The main manifestation of this viral infection is respiratory and cardiovascular; however, up-to-date knowledge of its probable neurologic complications is highly needed.

Evidence Acquisition: To provide up-to-date information on neurologic manifestation on coronaviruses, we concisely reviewed the neurologic manifestations and their complications. Using the keywords, coronavirus, corona, human coronaviruses (HCoVs), SARS, Middle East respiratory syndrome-related (MERS), coronavirus disease 2019 (COVID-19), manifestations, complications, and neurologic, all the relevant articles were retrieved from PubMed, reviewed, and critically analyzed.

Results: Although the main clinical manifestation of human coronaviruses is respiratory involvement and the main cause of death is acute respiratory failure, extra respiratory manifestations such as neurologic findings have been reported. Fortunately, the neurologic manifestations in COVID-19 have not been reported yet.

Conclusions: We need well-designed studies to monitor neurologic manifestations of COVID-19 in adults and children.

Keywords: HCoVs, COVID-19, SARS-CoV-2, Children, Neurologic, Manifestations, Complications

1. Context

Investigators described coronaviruses (CoVs) in the 1960s for the first time (1). The CoVs are a family of viruses that cause a variety of diseases in mammals and birds. The earliest reports were in chickens infected by two groups of viruses called human coronavirus 229E and human coronavirus OC43 and showed the clinical manifestations of the common cold (2). They belong to the subfamily Orthocoronavirinae, the member of the Coronaviridae family, the order of Nidovirales, and the kingdom of Riboviria (3, 4). They are a large family of single-stranded RNA viruses with a genome size of about 27 - 34 kb, which is the largest genome compared with other RNA viruses (5). Corona is a Latin term, meaning "crown", due to the surface covering in club-shaped protein spikes of virions (the infective form of a virus) by electron microscopy. The CoVs contain spike (S), envelope (E), membrane (M), and nucleocapsid (N) as proteins forming their overall structure. After entry into the host cell, the virus particle is uncoated, followed by en-

tering the genome to the cytoplasm (6).

There are seven strains of human CoVs, including Human coronavirus 229E (HCoV-229E), Human coronavirus HKU1, Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus NL63 (HCoV-NL63, new haven coronavirus), Human coronavirus OC43 (HCoV-OC43), SARS-CoV-2 or "novel coronavirus 2019" (2019-nCoV) (7).

The CoV subfamily has categorized into four genera of alpha, beta, gamma, and delta CoVs. The human coronaviruses (HCoVs) can be found in alpha CoVs (HCoV-229E and HCoV-NL63) and beta CoVs (HCoV-HKU1, HCoV-OC43, MERS-CoV, SARS-CoV, and SARS-CoV-2). The CoV family, including SARS-CoV, HCoV NL63, HKU1, MERS-CoV, and SARS-CoV-2, was identified in 2003, 2004, 2005, 2012, and 2019, respectively. Human-to-human transmission of CoVs is believed to occur through respiratory droplets from sneezing and coughing (8).

2. Evidence Acquisition

To provide up-to-date information on neurologic manifestation of CoVs, we concisely reviewed the neurologic manifestations and their complications. Using the keywords, including coronavirus, corona, HCoVs, SARS, MERS, COVID-19, manifestations, complications, and neurologic, all relevant articles were retrieved from PubMed, reviewed, and critically analyzed.

3. Results

3.1. Common Clinical Manifestations

Some CoVs only affect animals, but a number of them can also affect humans. Symptoms are different in different species: chickens represent upper respiratory tract infections (URTIs), whereas cows and pigs have diarrhea. HCoVs infections are linked to respiratory and extra respiratory tract symptoms and can affect the central nervous system. In addition, in contrast to different RNA viruses, HCoVs are easily mutated and recombined after infecting the same cells by various strains and resulting in a new virus with unexpected host ranges as well as pathogenicity (9).

Common HCoVs, such as 229E, NL63, OC43, and HKU1, result in mild to moderate URTIs, including common cold (runny nose, sore throat, headache, fever, cough, and feeling of illness). Investigators believed that CoVs account for 15% - 30% of total common colds among adults and children, primarily in the winter and early spring seasons. Most people could be infected with CoVs during their lives. Lower respiratory tract infections (LRTIs) are caused by HCoVs, like pneumonia or bronchitis (direct viral or secondary bacterial) (10), which mostly affect those with cardiopulmonary disease, various immune system deficiencies, infants, and elderly. Rare forms of HCoVs, including SARS and MERS, lead to both LRTIs and URTIs and can be lethal (10). The prevalence of atypical pneumonia was announced in December 2019 in Wuhan, China, as a new strain of CoV and called 2019-nCoV by the World Health Organization, which was then called SARS-CoV-2 according to the International Committee on Taxonomy of Viruses (11). Coronavirus disease 2019 (COVID-19) has special pathogenesis due to causing both LRTIs and URTIs and its lethal feature. The HCoVs were found in upper respiratory tract secretions collected in 30% of acute respiratory infections and wheezy bronchitis in cases younger than six years with recurrent respiratory infections (12). Abdominal pain, emesis, and diarrhea are the initial manifestations of acute infections by non-SARS HCoVs. Such findings have also

been announced, especially in the HCoV-OC43 and HCoV-NL63, that are possibly the direct outcomes of viral invasion along with the mucosa of the intestine (9).

3.2. Neurologic Manifestations

Members of Coronaviridae can cause respiratory, intestinal, hepatic, and neurological diseases of various severities in humans and animals. The clear involvement of several animal CoVs in acute and chronic neurologic diseases resulted in a search for similar pathogenicity of human CoVs. Community-acquired HCoVs can infect neural cells in vitro (13), and three-week-old mice develop generalized encephalitis after intracerebral inoculation with HCoV-OC43 (14). In another case report, HCoV-OC43 RNA was recovered from the brain, at autopsy, in an 11-month-old boy with severe combined immunodeficiency and acute encephalitis (15).

3.3. Demyelinating Disorders

The CoVOC43 was found in the cerebrospinal fluid (CSF) and nasopharyngeal secretions of a 15-year-old boy that admitted with the diagnosis of ADEM as the earliest announced link between HCoV and ADEM. This report confirms that CoV plays an important role in demyelinating disease in humans (16). Some investigators proposed a link between CoVs and multiple sclerosis (MS), but current evidence is inconclusive. T cell clones from patients with MS have been shown to react to both HCoV-229E antigens and myelin basic protein, suggesting molecular mimicry as a basis of pathogenesis (16). Some, but not all, investigators have detected RNA of the human CoVs, HCoV-OC43, and HCoV-229E, more frequently in brain tissue of cases with MS through reverse-transcriptase polymerase chain reaction than in healthy individuals (17). Despite these reports, an etiologic link between CoVs and demyelinating disorders such as MS or ADEM has not been proven.

Arabi et al. (18) reported a severe neurologic syndrome associated with MERS CoV infections. The neurologic symptoms are alterations in mental state that range from confusion to coma, ataxia, and focal motor impairments. According to the results of brain MRI, new-onset widespread, two-sided hyperintensities on T2WI in white matter as well as subcortical regions of the frontal, temporal, and parietal lobes, the basal ganglia and corpus callosum, pons, cerebellum, and upper cervical cord (18). The HCoVs could cause neurological symptoms such as seizures and meningoencephalitis in children (19).

3.4. Acute Flaccid Paralysis

In particular, HCoV OC43 is a neurotrophic, neuroinvasive, and neuroinflammatory virus. Experimental animal studies reported that HCoV OC43 causes flaccid paralysis and demyelination (AFP) (20). Although HCoVs as a cause of AFP has not been reported until now (19), HCoV 229E and OC43 co-infection may cause respiratory failure and AFP (21).

3.5. Neurologic Complications During Treatment

Sometimes neurologic complications may be seen during the treatment of HCoVs infections. Kim et al. (22) revealed that neurological symptoms could be observed throughout or following MERS-CoV therapy. Bickerstaff's encephalitis overlapping with Guillain-Barre syndrome, intensive-care-unit-acquired weakness, or other toxic or infectious neuropathies were the possible diagnoses presented for these four cases out of 23 referred MERS cases (22).

3.6. Neurologic Complications of COVID-19

Although from the December 2019, outbreak of a novel coronavirus (SARS-CoV-2) or COVID-19 started in Wuhan and has become a global threat to human health in a short time, fortunately, significant neurological manifestations were not reported until now.

4. Conclusions

HCoVs can infect humans and animals. Moreover, HCoVs infections are accompanied by common respiratory and uncommon extra respiratory symptoms and can affect the central nervous system. The HCoVs have been causing worldwide outbreaks with high morbidity and mortality. Fortunately, neurological manifestations are not common but reported during the acute phase and treatment period.

Footnotes

Authors' Contribution: Study concept and design: Mahmoud Reza Ashrafi, Morteza Heidari, and Ali Reza Tavassoli. Drafting the manuscript: Reza Azizimalamir, Reza Shervin Bady, Mohammad Vafae-Shahi, and Ali Nikkhah. Critical revision of the manuscript for important intellectual content: Mahmoud Reza Ashrafi, Morteza Heidari, and Hadi Montazerlotfelahi. Study supervision: Mahmoud Reza Ashrafi and Morteza Heidari.

Conflict of Interests: Authors declare no conflict of interest.

Funding/Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. *Pediatr Infect Dis J*. 2005;24(11 Suppl):S223-7. discussion S226. doi: [10.1097/01.inf.0000188166.17324.60](https://doi.org/10.1097/01.inf.0000188166.17324.60). [PubMed: 16378050].
2. Geller C, Varbanov M, Duval RE. Human coronaviruses: Insights into environmental resistance and its influence on the development of new antiseptic strategies. *Viruses*. 2012;4(11):3044-68. doi: [10.3390/v4113044](https://doi.org/10.3390/v4113044). [PubMed: 23202515]. [PubMed Central: PMC3509683].
3. Adams MJ, Lefkowitz EJ, King AM, Harrach B, Harrison RL, Knowles NJ, et al. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2016). *Arch Virol*. 2016;161(10):2921-49. doi: [10.1007/s00705-016-2977-6](https://doi.org/10.1007/s00705-016-2977-6). [PubMed: 27424026]. [PubMed Central: PMC7086986].
4. Walker PJ, Siddell SG, Lefkowitz EJ, Mushegian AR, Dempsey DM, Dutilleul BE, et al. Changes to virus taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2019). *Arch Virol*. 2019;164(9):2417-29. doi: [10.1007/s00705-019-04306-w](https://doi.org/10.1007/s00705-019-04306-w). [PubMed: 31187277].
5. Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. *J Virol*. 2016;90(16):7415-28. doi: [10.1128/JVI.00080-16](https://doi.org/10.1128/JVI.00080-16). [PubMed: 27279608]. [PubMed Central: PMC4984655].
6. Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. *Methods Mol Biol*. 2015;1282:1-23. doi: [10.1007/978-1-4939-2438-7_1](https://doi.org/10.1007/978-1-4939-2438-7_1). [PubMed: 25720466]. [PubMed Central: PMC4369385].
7. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. *Adv Virus Res*. 2018;100:163-88. doi: [10.1016/bs.aivir.2018.01.001](https://doi.org/10.1016/bs.aivir.2018.01.001). [PubMed: 29551135]. [PubMed Central: PMC7112090].
8. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro Surveill*. 2020;25(4). doi: [10.2807/1560-7917.ES.2020.25.4.2000058](https://doi.org/10.2807/1560-7917.ES.2020.25.4.2000058). [PubMed: 32019669]. [PubMed Central: PMC7001239].
9. Principi N, Bosis S, Esposito S. Effects of coronavirus infections in children. *Emerg Infect Dis*. 2010;16(2):183-8. doi: [10.3201/eid1602.090469](https://doi.org/10.3201/eid1602.090469). [PubMed: 20113545]. [PubMed Central: PMC2957994].
10. Forgie S, Marrie TJ. Healthcare-associated atypical pneumonia. *Semin Respir Crit Care Med*. 2009;30(1):67-85. doi: [10.1055/s-0028-1119811](https://doi.org/10.1055/s-0028-1119811). [PubMed: 19199189].
11. Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Clinical features and treatment of 2019-nCoV pneumonia patients in Wuhan: Report of a couple cases. *Viral Sin*. 2020. doi: [10.1007/s12250-020-00203-8](https://doi.org/10.1007/s12250-020-00203-8). [PubMed: 32034637].
12. Isaacs D, Flowers D, Clarke JR, Valman HB, MacNaughton MR. Epidemiology of coronavirus respiratory infections. *Arch Dis Child*. 1983;58(7):500-3. doi: [10.1136/adc.58.7.500](https://doi.org/10.1136/adc.58.7.500). [PubMed: 6307189]. [PubMed Central: PMC1628163].
13. Arbour N, Ekande S, Cote G, Lachance C, Chagnon F, Tardieu M, et al. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. *J Virol*. 1999;73(4):3326-37. [PubMed: 10074187]. [PubMed Central: PMC104097].
14. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected by human coronavirus OC43. *Virology*. 2003;315(1):20-33. doi: [10.1016/s0042-6822\(03\)00323-4](https://doi.org/10.1016/s0042-6822(03)00323-4). [PubMed: 14592756]. [PubMed Central: PMC7126296].

15. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, et al. Human coronavirus OC43 associated with fatal encephalitis. *N Engl J Med*. 2016;**375**(5):497-8. doi: [10.1056/NEJMc1509458](https://doi.org/10.1056/NEJMc1509458). [PubMed: [27518687](https://pubmed.ncbi.nlm.nih.gov/27518687/)].
16. Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. *Clin Immunol*. 2007;**123**(3):258-67. doi: [10.1016/j.clim.2007.02.002](https://doi.org/10.1016/j.clim.2007.02.002). [PubMed: [17448727](https://pubmed.ncbi.nlm.nih.gov/17448727/)]. [PubMed Central: [PMC7106099](https://pubmed.ncbi.nlm.nih.gov/PMC7106099/)].
17. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. *J Virol*. 2000;**74**(19):8913-21. doi: [10.1128/jvi.74.19.8913-8921.2000](https://doi.org/10.1128/jvi.74.19.8913-8921.2000). [PubMed: [10982334](https://pubmed.ncbi.nlm.nih.gov/10982334/)]. [PubMed Central: [PMC102086](https://pubmed.ncbi.nlm.nih.gov/PMC102086/)].
18. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). *Infection*. 2015;**43**(4):495-501. doi: [10.1007/s15010-015-0720-y](https://doi.org/10.1007/s15010-015-0720-y). [PubMed: [25600929](https://pubmed.ncbi.nlm.nih.gov/25600929/)]. [PubMed Central: [PMC4521086](https://pubmed.ncbi.nlm.nih.gov/PMC4521086/)].
19. Dominguez SR, Robinson CC, Holmes KV. Detection of four human coronaviruses in respiratory infections in children: A one-year study in Colorado. *J Med Virol*. 2009;**81**(9):1597-604. doi: [10.1002/jmv.21541](https://doi.org/10.1002/jmv.21541). [PubMed: [19626607](https://pubmed.ncbi.nlm.nih.gov/19626607/)]. [PubMed Central: [PMC2879166](https://pubmed.ncbi.nlm.nih.gov/PMC2879166/)].
20. Brison E, Jacomy H, Desforges M, Talbot PJ. Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. *J Virol*. 2011;**85**(23):12464-73. doi: [10.1128/JVI.05576-11](https://doi.org/10.1128/JVI.05576-11). [PubMed: [21957311](https://pubmed.ncbi.nlm.nih.gov/21957311/)]. [PubMed Central: [PMC3209392](https://pubmed.ncbi.nlm.nih.gov/PMC3209392/)].
21. Turgay C, Emine T, Ozlem K, Muhammet SP, Haydar AT. A rare cause of acute flaccid paralysis: Human coronaviruses. *J Pediatr Neurosci*. 2015;**10**(3):280-1. doi: [10.4103/1817-1745.165716](https://doi.org/10.4103/1817-1745.165716). [PubMed: [26557177](https://pubmed.ncbi.nlm.nih.gov/26557177/)]. [PubMed Central: [PMC4611905](https://pubmed.ncbi.nlm.nih.gov/PMC4611905/)].
22. Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurological complications during treatment of Middle East respiratory syndrome. *J Clin Neurol*. 2017;**13**(3):227-33. doi: [10.3988/jcn.2017.13.3.227](https://doi.org/10.3988/jcn.2017.13.3.227). [PubMed: [28748673](https://pubmed.ncbi.nlm.nih.gov/28748673/)]. [PubMed Central: [PMC5532318](https://pubmed.ncbi.nlm.nih.gov/PMC5532318/)].